Piper Sandler analyst Matt O’Brien lowered the firm’s price target on Integra LifeSciences to $44 from $55 and keeps a Neutral rating on the shares. The analyst updated the company’s model to account for its updated guidance.
Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
Published first on TheFly
See the top stocks recommended by analysts >>
Read More on IART: